Allakos (ALLK) News Today → AI finds its first serious application (From Wall Street Star) (Ad) Free ALLK Stock Alerts $1.01 -0.01 (-0.98%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMarket Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developmentsmarkets.businessinsider.com - April 24 at 4:44 AMAllakos (NASDAQ:ALLK) Trading Down 3.3%marketbeat.com - April 11 at 1:42 AM3 Biotech Stocks to Dump Before They Go to Zeroinvestorplace.com - April 9 at 6:31 AMAllakos Inc. (NASDAQ:ALLK) to Post FY2025 Earnings of ($0.61) Per Share, Leerink Partnrs Forecastsmarketbeat.com - March 20 at 6:55 AMHold Rating on Allakos Amidst Cautious Optimism for AK006 Programmarkets.businessinsider.com - March 19 at 8:23 AMShort Interest in Allakos Inc. (NASDAQ:ALLK) Increases By 9.1%marketbeat.com - March 17 at 9:16 AMAllakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4finance.yahoo.com - March 16 at 8:16 AMHold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developmentsmarkets.businessinsider.com - March 15 at 6:18 PMBuy Rating Maintained for Century Therapeutics with Increased Price Target Amid Promising Trials and Strong Financialsmarkets.businessinsider.com - March 15 at 1:18 PMTD Cowen Remains a Hold on Allakos (ALLK)markets.businessinsider.com - March 15 at 1:27 AMALLK Stock Earnings: Allakos Misses EPS for Q4 2023investorplace.com - March 14 at 10:03 PMAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 14 at 4:02 PMAllakos (ALLK) Scheduled to Post Earnings on Mondaymarketbeat.com - March 3 at 7:31 AMAllakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024finanznachrichten.de - February 26 at 1:12 PMAllakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024globenewswire.com - February 26 at 7:02 AMALLK Sep 2024 2.000 callfinance.yahoo.com - February 17 at 11:13 PMALLK Sep 2024 2.500 callfinance.yahoo.com - February 17 at 8:12 AMALLK Mar 2024 1.500 callfinance.yahoo.com - February 17 at 8:12 AMAllakos Inc.: Allakos Announces Publication Highlighting AK006 Mast Cell Inhibitionfinanznachrichten.de - February 12 at 8:01 AMAllakos Announces Publication Highlighting AK006 Mast Cell Inhibitionfinance.yahoo.com - February 12 at 8:01 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLKstockhouse.com - January 28 at 1:37 PMHere's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeksfinance.yahoo.com - January 18 at 11:36 AMJMP Securities Cuts Allakos (NASDAQ:ALLK) Price Target to $3.00marketbeat.com - January 17 at 2:32 PMAllakos price target lowered by 50c at Barclays, here's whyrealmoney.thestreet.com - January 17 at 12:40 PMAllakos extends losses as analysts downgrade on Phase 2 setbackmsn.com - January 17 at 12:40 PMAllakos (NASDAQ:ALLK) Lowered to Hold at Jefferies Financial Groupmarketbeat.com - January 17 at 7:12 AMAllakos just downgraded at Cantor Fitzgerald, here's whyrealmoney.thestreet.com - January 16 at 8:56 PMAllakos just downgraded at LifeSci Capital, here's whyrealmoney.thestreet.com - January 16 at 8:56 PMIs Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com - January 16 at 3:56 PMCantor Fitzgerald Lowers Allakos (NASDAQ:ALLK) to Neutralmarketbeat.com - January 16 at 2:42 PMWhy Is Allakos (ALLK) Stock Down 57% Today?investorplace.com - January 16 at 1:10 PMAllakos to Cut Workforce by Half Amid Results from Lirentelimab Trialsmarketwatch.com - January 16 at 10:48 AMAllakos Shares Dive 61% Following Pivot from Lirentelimab After Trial Resultsmarketwatch.com - January 16 at 10:48 AMAllakos Announces a Restructuring to Focus on Development of AK006finance.yahoo.com - January 16 at 10:48 AMElevai Labs, Allakos, TransCode Therapeutics among healthcare moversmsn.com - January 16 at 10:48 AMAllakos crashes on restructuring plansmsn.com - January 16 at 10:48 AMAllakos to stop further development of skin disease drug, plans job cutsreuters.com - January 16 at 10:48 AMAllakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpointsfinance.yahoo.com - January 16 at 10:48 AMmarketbeat.com - January 16 at 6:58 AMAnalysts Offer Insights on Healthcare Companies: Allakos (ALLK) and Crinetics Pharmaceuticals (CRNX)markets.businessinsider.com - December 20 at 1:06 AMWilliam Blair Upgrades Allakos (ALLK)msn.com - December 19 at 9:15 AMAllakos Analyst Turns Bullish, Sees 'Significant Upside' If Study Results Are Positivemarkets.businessinsider.com - December 18 at 4:09 PMAllakos (NASDAQ:ALLK) Upgraded to "Outperform" at William Blairmarketbeat.com - December 18 at 7:05 AMAllakos assumed with a Buy at Jefferiesrealmoney.thestreet.com - December 8 at 7:37 PMBuy Rating for Allakos: Anticipating Lirentelimab’s Market Catalyst and Blockbuster Potentialmarkets.businessinsider.com - November 28 at 2:46 PMOhio's VC vehicle has attracted investment and jobs – but could cost taxpayers $100Mbizjournals.com - November 16 at 3:47 PMAllakos GAAP EPS of -$0.52 misses by $0.06msn.com - November 15 at 6:33 AMPromising Developments and Solid Financials Drive Buy Rating for Allakos: An Analysis of Lirentelimab Trials and Investment Potentialmarkets.businessinsider.com - November 15 at 6:33 AMAllakos Inc.: Allakos Provides Business Update and Reports Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 14 at 7:26 AMTD Cowen Reaffirms Their Hold Rating on Allakos (ALLK)markets.businessinsider.com - November 14 at 7:26 AM Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address $25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time… Go here to watch the most recent trading workshop video at no charge. ALLK Media Mentions By Week ALLK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLK News Sentiment▼0.800.41▲Average Medical News Sentiment ALLK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLK Articles This Week▼11▲ALLK Articles Average Week Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Reviva Pharmaceuticals News Today Milestone Pharmaceuticals News Today Connect Biopharma News Today Genelux News Today DiaMedica Therapeutics News Today Seres Therapeutics News Today Oramed Pharmaceuticals News Today Aclaris Therapeutics News Today Barinthus Biotherapeutics News Today Clearside Biomedical News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
